CD52 CD52 molecule
ENSG00000169442 · protein coding · Open Targets profile
May play a role in carrying and orienting carbohydrate, as well as having a more specific role.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Structure with Ligand
- Antibody
- Approved Drug, GO CC high conf, UniProt loc med conf, UniProt SigP or TMHMM
gnomAD loss of function constraint: o/e 0.7877100110054016 (upper bound 2.479599952697754). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
No named investigators on registry trials of CD52's approved or late-stage drugs in the last three years.
No terminated, withdrawn or suspended trials of CD52's drugs are registered
All 2 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.